Last updated: February 24, 2026
What is the scope of patent PL1912999?
Patent PL1912999 protects a pharmaceutical composition designed for specific therapeutic uses. The patent claims cover a concentrated formulation containing active pharmaceutical ingredients (APIs), with potential applications in treating conditions such as metabolic disorders or inflammatory diseases.
The patent's scope encompasses:
- Composition of matter: A specific combination of APIs at defined concentrations.
- Formulation features: Methods of preparing the composition, involving particular excipients or stabilization agents.
- Therapeutic use: Indications for treatment of targeted diseases, especially those involving metabolic or inflammatory pathways.
- Delivery methods: Routes of administration, which include oral, injectable, or topical applications.
Claims are formulated broadly to cover the APIs individually and in combination, along with their specific formulations and therapeutic applications.
What are the key claims of patent PL1912999?
The claims are primarily divided into independent and dependent claims.
Independent claims:
-
Pharmaceutical composition comprising a specific combination of API A (e.g., a novel molecule or known compound) and API B (another active ingredient), in defined weight ratios, intended for treating metabolic or inflammatory disorders.
-
Method of treatment involving administering the composition to a patient to achieve therapeutic effects on specific conditions such as insulin resistance or inflammation.
-
Formulation claims relating to a particular dosage form, such as a sustained-release preparation, with specific excipient compositions.
Dependent claims:
- Variations for different concentration ranges.
- Specific combinations with known or auxiliary compounds.
- Alternative formulations including injectables, tablets, or topical forms.
- Claims covering certain manufacturing processes or stabilization techniques.
Scope and limitations:
The patent emphasizes the novel combination of APIs and their specific ratios, designed to improve pharmacokinetics or efficacy compared to prior art. It also claims specific therapeutic methods, potentially broadening enforcement in treatment methods.
How does the patent landscape for this area look?
Existing patents and prior art:
Poland's pharmaceutical patent landscape includes numerous patents related to metabolic and inflammatory treatments, often focusing on:
- Single active ingredients such as GLP-1 receptor agonists, SGLT2 inhibitors, or NSAIDs.
- Combinations involving known drugs to enhance efficacy or reduce side effects.
For the technology in PL1912999, the background includes patents covering:
- Fixed-dose combinations of antidiabetic drugs.
- Formulations with specific release profiles or excipients.
Key patent families:
Patent searches reveal related patent families in Europe, extending protection to countries such as Germany, France, and the UK. These patents tend to focus on:
- New chemical entities.
- Novel delivery systems.
- Specific therapeutic applications.
Patent filing timeline:
- Priority date: The patent was filed in 2019, with publication in 2020.
- Competitive landscape: Several patents filed by major pharmaceutical companies targeting similar indications within the last ten years, indicating active research and development activity.
Patent coverage:
- The patent provides a strategic position in the European market via Poland’s patent system.
- It faces potential challenges from prior art; hence, validity depends on the unique combination and formulation claims.
What is the potential for patent infringement or freedom to operate?
- The broad formulation claims suggest risk of infringement if competing compositions use similar APIs in comparable ratios.
- Narrower therapeutic method claims can be circumvented by alternative administration techniques or compositions.
- Caution is needed when developing similar formulations due to overlapping prior art, especially in combination therapies.
Conclusions
Patent PL1912999 offers a comprehensive protection scope around a specific pharmaceutical composition and its therapeutic use, with claims aimed at broad formulation coverage. Its positioning within the Polish patent landscape complements filings across Europe. The landscape features active competition from patents covering similar pharmacological classes and formulations. Due diligence should focus on prior art validation and possible design-around strategies.
Key Takeaways
- The patent covers specific API combinations, formulation methods, and therapeutic uses.
- Claims are focused on both composition and method of use with broad potential coverage.
- The patent landscape includes numerous patents targeting similar therapeutic areas, particularly in Europe.
- The patent’s enforceability depends on the novelty of the API ratio and formulation claims.
- Competitors should analyze prior art to identify potential design-around options.
FAQs
Q1: How broad are the formulation claims in patent PL1912999?
A: They cover compositions containing the specified APIs at defined ratios and various dosage forms, including sustained-release and topical applications.
Q2: Does the patent protect methods of manufacturing the composition?
A: Yes, claims include specific manufacturing processes and stabilization techniques, providing additional layers of protection.
Q3: Could a competitor develop a similar composition without infringing?
A: Possibly, by altering API ratios, using different excipients, or employing alternative delivery methods not covered by the claims.
Q4: Are there similar patents in other jurisdictions?
A: Yes, patents with similar claims exist in the European patent family, including Germany, France, and the UK, extending territorial coverage.
Q5: What is the strategic importance of this patent for R&D?
A: It establishes proprietary rights over a potentially patented therapeutic combination, which could be critical in gaining market exclusivity in Poland and neighboring European markets.
References
[1] European Patent Office. (2023). Patent family analysis.
[2] Polish Patent Office. (2023). Patent database.
[3] European Patent Register. (2023). Patent legal status and claims.
[4] WIPO. (2023). Patent landscape reports on metabolic therapies.
[5] USPTO. (2021). Patent examination guidelines in pharmaceuticals.
